Presented by: Fanny Caputo, Ph.D., SINTEF, and Christoph Johann, Ph.D., Wyatt Technology
Presented Live: December 15, 2020
Multi-detector asymmetric-flow field-flow fractionation (MD-AF4) has been recognized as an invaluable tool for the characterization of particle size, polydispersity, drug loading and stability of nanopharmaceuticals. The application of robust and high-quality standard operating procedures (SOPs) is critical for accurate and reliable measurements, especially as these complex drug nano-formulations are most often inherently polydisperse.
A unique international collaboration, involving two state-of-the-art infrastructures in the field of nanomedicine—the European Nanomedicine Characterization Laboratory (EUNCL) and the National Cancer Institute Nanotechnology Characterization Laboratory (NCI-NCL)—has led to the development of a robust SOP for the measurement of physical-chemical properties of nanopharmaceuticals by MD-AF4. After a brief overview of MD-AF4 principles and instrumentation, this webinar presents examples of how MD-AF4 quantifies key quality attributes of complex nanomedicine formulations such as particle size distributions, shape, concentration and stability, using the SOP guidelines. Particular focus is given to the characterization of liposomal products and of lipid-based nanoparticles (LNPs) for RNA delivery. Finally, current efforts within ASTM for standardization of methods based on MD-AF4 are presented.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.